全文获取类型
收费全文 | 101995篇 |
免费 | 7764篇 |
国内免费 | 376篇 |
专业分类
耳鼻咽喉 | 1126篇 |
儿科学 | 2530篇 |
妇产科学 | 1649篇 |
基础医学 | 14466篇 |
口腔科学 | 2193篇 |
临床医学 | 10435篇 |
内科学 | 21634篇 |
皮肤病学 | 1795篇 |
神经病学 | 10896篇 |
特种医学 | 4198篇 |
外国民族医学 | 6篇 |
外科学 | 14619篇 |
综合类 | 1251篇 |
一般理论 | 73篇 |
预防医学 | 7884篇 |
眼科学 | 1720篇 |
药学 | 6905篇 |
中国医学 | 111篇 |
肿瘤学 | 6644篇 |
出版年
2023年 | 525篇 |
2022年 | 910篇 |
2021年 | 2143篇 |
2020年 | 1320篇 |
2019年 | 1972篇 |
2018年 | 2426篇 |
2017年 | 1785篇 |
2016年 | 2134篇 |
2015年 | 2480篇 |
2014年 | 3265篇 |
2013年 | 4296篇 |
2012年 | 6656篇 |
2011年 | 6705篇 |
2010年 | 3959篇 |
2009年 | 3611篇 |
2008年 | 5931篇 |
2007年 | 6422篇 |
2006年 | 5953篇 |
2005年 | 5897篇 |
2004年 | 5507篇 |
2003年 | 4912篇 |
2002年 | 4871篇 |
2001年 | 1867篇 |
2000年 | 1782篇 |
1999年 | 1658篇 |
1998年 | 1215篇 |
1997年 | 996篇 |
1996年 | 807篇 |
1995年 | 815篇 |
1994年 | 695篇 |
1993年 | 635篇 |
1992年 | 1151篇 |
1991年 | 1067篇 |
1990年 | 1010篇 |
1989年 | 970篇 |
1988年 | 863篇 |
1987年 | 810篇 |
1986年 | 831篇 |
1985年 | 826篇 |
1984年 | 669篇 |
1983年 | 578篇 |
1982年 | 553篇 |
1981年 | 453篇 |
1980年 | 394篇 |
1979年 | 514篇 |
1978年 | 406篇 |
1977年 | 367篇 |
1975年 | 327篇 |
1974年 | 355篇 |
1973年 | 343篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Martin F. Shapiro 《Journal of general internal medicine》2015,30(10):1392-1393
12.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
13.
14.
Michael E Egger Joanna M Ohlendorf Charles R Scoggins Kelly M McMasters Robert C G Martin II 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2015,17(9):839-845
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery. 相似文献
15.
16.
17.
18.
19.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
20.